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Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syn-
drome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD)
of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate
clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera
in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration
of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the
passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of
the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted
in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative
control antibody. The murine antisera used were derived from mice which had been primed sub-
cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium
phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse
micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-
Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisa-
tion capacity for clinical strains of MERS-CoV.
Crown Copyright  2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Middle East respiratory disease syndrome (MERS) first
emerged in 2012 in Saudi Arabia [1,2]. Since then, there have been
an estimated 2311 laboratory-confirmed cases with 811 deaths,
reported from a total of 27 countries in the eastern Mediterranean
region and from 12 countries elsewhere [1]. Saudi Arabia, however,
remains the main focus of infection and a disease outbreak in
South Korea involving 186 cases was traced back to an index case
who had travelled from Saudi Arabia. Whilst the incidence of MERS
cases in Saudi Arabia peaked in 2014, there are still a significantnumber of cases reported from the country and in the period
September 2012–May 2018, there were 1844 cases including 716
deaths with a case fatality rate of 38.8% [1]. MERS coronavirus
(MERS-CoV) is a member of the betacoronavirus genus [3] and as
for other betacoronaviruses, bats may provide a natural reservoir
for the virus [3,4], but high levels of antibodies to MERS-CoV in
dromedary camels [5] suggest that the dromedary camel is the
principal source for animal-to-human transmission of MERS-CoV
[6]. However, evidence of human-to-human transmission comes
from the reporting of outbreaks in countries remote from Saudi
Arabia such as the UK, Europe, USA, and China where small out-
breaks have also occurred [1].
MERS-CoV is an enveloped, positive-sense, single-stranded RNA
virus [3]. The virus possesses an envelope-anchored trimeric spike
protein which binds to the human receptor dipeptidyl peptidase 4
(DPP4 or CD26) and gains host cell entry by the fusion of viral and
host membranes [7]. The spike protein comprises an S1 sub-unit
and a membrane fusion S2 sub-unit. In the coronaviruses, the S1
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domains and for MERS-CoV, it is the C-terminal sub-domain that
comprises the receptor-binding domain (RBD) [8]. The RBD also
incorporates a receptor-binding motif at its C-terminal and the
crystal structures of MERS-CoV RBD [8] and of the RBD bound to
the extracellular domain of human DPP4 have been reported [9].
The RBDs of the coronaviruses represent vaccine and therapeu-
tic targets and the RBD of MERS-CoV as a vaccine antigen has been
demonstrated to induce neutralising antibody [10] and to protect
mice transduced with a viral vector expressing hDPP4, or non-
human primates from viral challenge [11–15]. There are significant
ongoing efforts to develop vaccines for MERS-CoV infection,
predominantly involving live attenuated viral vectors such as
adenovirus, modified vaccinia Ankara or measles [16] to induce
anti-viral immunity and some of these vaccines are already in
clinical trials.
Here, we were interested to determine the relative importance
of inducing systemic and/or mucosal immunity in vaccination to
protect against MERS-CoV, an infection predominantly of the respi-
ratory tract and lungs. To this end, we have used a dual route
immunisation regimen in Balb/c mice to induce both systemic
and mucosal immunity, to generate RBD-specific murine antisera.
Initially, we immunised Balb/c mice sub-cutaneously (s.c.) with
RBD-Fc in the MF59 adjuvant to induce RBD-specific IgG. Subse-
quently, we have immunised further groups of Balb/c mice by s.c.
priming and per oral (p.o.) boosting with the RBD-Fc, to induce
both systemic IgG and mucosal IgA responses. To do this, we have
used novel formulations of RBD-Fc coated onto microcrystals
formed from histidine or glutamine and also incorporating calcium
phosphate for sub-cutaneous priming [17], whilst the formulation
for oral boosting comprised RBD-Fc in reverse micelles dispersed in
a self-emulsifying oil phase, which has been optimised from previ-
ous formulations [18,19]. The advantages of these formulations are
that they are very stable under extremes of temperature [20]. Fur-
thermore, on translation to the clinic, only one injected priming
dose would be required, followed by a p.o. booster dose; the latter
could be self-administered in capsule form. We have compared the
relative abilities of the two sources of antiserum to neutralise clin-
ical isolates of MERS-CoV in vitro. To do this, we have used two
clinical strains of MERS-CoV (Erasmus Medical Center 2012 or
EMC2012 and London1-2012:), each of which were derived from
severely-ill individuals who had contracted the virus in the Middle
East in 2012. Subsequent sequencing of the polymerase gene from
these isolates indicated them to be newly-emerged members of
the betacoronavirus genus with a close sequence homology and
phylogenetic relationship to the bat coronaviruses HKU4 and
HKU-5 [21,22].
Mice are not naturally susceptible to MERS-CoV infection, but
susceptibility can be induced by the administration of an aden-
ovirus vector which induces expression of the human receptor
(hDPP4/CD26) for the virus in vivo for a limited time, providing a
non-lethal murine model of the disease [23]. We have used this
transduced mouse model to test the capacity of the antiserum
derived from the dual route immunisation to neutralise MERS-
CoV in vivo, by passive transfer prior to challenge with the
EMC2012 strain and we have demonstrated a significant reduction
in viral load in lung tissue in transduced mice.2. Materials and methods
2.1. Expression and purification of RBD
The RBD was synthesised and expressed according to methods
adapted from Du et al. [10]. In brief, a single DNA fragment con-
taining an in-frame fusion of the coding sequences for the humanIL2 signal peptide, the RBD and human IgG1-Fc was synthesised.
This was transferred into the plasmid pEF-DEST51 (Invitrogen) so
that the target sequence was expressed as a secreted protein with
a C-terminal human IgG1 Fc tag. This construct was transfected by
cationic transfection into human embryo kidney (HEK) cells in sus-
pension (FSHEK) or adherent HEK cells stably expressing the Sv40
large T antigen (293FT), using serum-free media and incubated for
4–7 days. Small scale purifications of RBD-Fc were performed using
Protein A chromatography. For this, medium from the transfected
cells was treated with ammonium sulphate to precipitate the pro-
tein, prior to dialysis and resuspension in buffers for binding to
Protein A beads. The latter were washed and eluted with buffer
containing 1 M urea. Protein concentration was determined by
UV absorbance spectroscopy and purity was estimated by SDS-
PAGE with Coomassie staining and subsequent optical densitome-
try using a Syngene G:Box imaging system.
2.2. Formulation of RBD-Fc for injected and oral immunisation
The RBD-Fc was incorporated on glutamine calcium phosphate
(CaP) microcrystals for s.c. immunisation, using methodology
adapted from [17]. Briefly, aqueous mixtures of RBD-Fc with
sodium orthophosphate and glutamine were precipitated as CaP
protein-coated microcrystals (CaP-PCMC), by addition to of a 19-
fold excess of isopropanol containing dissolved calcium chloride.
The resultant suspension contained self-assembled microcrystals
comprising a glutamine core with the RBD-Fc protein embedded
in a thin surface layer of CaP (now termed RBD-Fc-PCMC). The
PCMC were isolated by vacuum filtration and dried to a powder.
Protein content and integrity was determined by ELISA and SDS-
PAGE.
For oral dosing, the RBD-Fc was incorporated in mineral oil with
added excipients using methodology adapted from [18,19]. The
oral formulation comprised RBD-Fc with the mucosal adjuvant
cholera toxin B sub-unit (CTB), retinoic acid (RA), vitamin D, E
and trehalose debehenate (TDB), a synthetic analog of the
mycobacterial trehalose dimycolate [25] and imiquimod, a TLR
7/8 agonist [26].
2.3. Immunisation and sampling of mice
Specific pathogen-free female Balb/c mice (6–8 weeks of age)
were obtained from a commercial breeder and used throughout
this study. On receipt, mice were randomised for allocation to
cages and given free access to food, water and environmental
enrichment. Mice were fully acclimatised to the animal housing
facility for at least five days prior to any procedure. All animal pro-
cedures were performed in accordance with UK legislation as sta-
ted in the UK Animal (Scientific Procedures) Act 1986. The
Institutional Animal Care and Use Committee approved the rele-
vant Project licence.
Naïve mice were randomised for allocation to a treatment
group (typically 5 per group) and immunised in one of two regi-
mens: either with a s.c. priming dose followed by two s.c. doses,
given at 10 and 31 days after the prime; alternatively, mice
received a s.c. priming dose followed by an oral or s.c. booster dose
21 days after the prime (Table 1). For s.c. immunisation, mice
received 2.5 lg of RBD-Fc-PCMC in 0.1 ml PBS injection volume,
whereas for all per oral (p.o.) dosing, mice received 25 lg of
RBD-Fc in a total volume of 0.1 ml mineral oil (MO), by oral gavage.
Where RBD-Fc was administered s.c. in the conventional adjuvants
MF59 or alhydrogel, MF59 (Novartis, US) was used in a 1:1 ratio by
volume with RBD-Fc in PBS, whilst alhydrogel (Brenntag Biosector,
Denmark) was used in a 1:5 ratio with RBD-Fc by volume in PBS.
At selected intervals after dosing, mice were blood-sampled
from the tail vein for assay of specific antibody titre. At the end
Table 1
Murine Immunisation regimens.
Regimen 1 Day 0 Day 10 Day 31
Treatment group 1 Prime s.cut with 2.5 lg RBD-Fc in alhydrogel Boost s.cut with 2.5 lg RBD-Fc in alhydrogel Boost s.cut with 2.5 lg RBD-Fc in alhydrogel
Treatment group 2 Prime s.cut with 2.5 lg RBD-Fc in MF59 Boost s.cut with 2.5 lg RBD-Fc in MF59 Boost s.cut with 2.5 lg RBD-Fc in MF59
Regimen 2 Day 0 Day 21
Treatment group 1 Prime s.cut with 2.5 lg RBD-Fc on PCMC Boost s.cut with 2.5 lg RBD-Fc on PCMC
Treatment group 2 Prime s.cut with 2.5 lg RBD-Fc on PCMC Boost p.o. with 25 lg RBD-Fc in oil vehicle
Treatment group 3 Prime p.o. with 25 lg RBD-Fc in oil vehicle Boost p.o. with 25 lg RBD-Fc in oil vehicle
Treatment group 4 Prime s.cut with 2.5 lg RBD-Fc in MF59 Boost s.cut with 2.5 lg RBD-Fc in MF59
Treatment group 5 Empty microcrystals Oral vehicle
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anaesthetised for collection of blood by cardiac puncture, then
culled prior to removal of small and large intestines for collection
of faecal pellets for extraction of IgA.
2.4. Serological assays for titre and neutralising antibody
Titres of RBD-Fc-specific antibody in serum samples were
determined by ELISA. In brief, test sera were bound to microtitre
plates pre-coated with RBD-Fc and antibody binding was detected
with an HRPO-labelled secondary antibody to mouse IgG, IgG1,
IgG2a or IgA (Bio-Rad). A standard curve for calibration comprising
the relevant murine Ig isotype (Sigma) captured with an anti-Fab
reagent, was included on each plate. Plates were developed by
the addition of 2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid) diammonium salt (ABTS) substrate (Sigma) and optical den-
sity (OD) was read at 414 nm (Multiskan plate reader). For assay
of antibody in faecal samples, faecal pellets were extracted in sup-
plemented PBS as described previously [20]. In brief, 10 ml of cold
PBS was prepared, supplemented with 1 tablet of complete mini
protease inhibitor cocktail (Sigma) and 5 ll Tween 20 were added.
To 0.1 g faecal pellets, 1 ml of supplemented PBS was added and
left at room temperature for 5 min. Samples were vortexed for
approximately 30 s, incubated on ice for a further 20 min. and then
centrifuged (15,000g, 5 min.). Supernatants were retained and
stored at 80 C pending assay. The faecal extracts were assayed
for specific IgG and IgA content, by ELISA, as for serum samples.
Antibody concentrations in all samples were determined from
the relevant standard curves using Ascent software with four-
parameter logistic curve-fitting and reported in ng/ml or lg/ml
serum or faecal extract, as appropriate.
2.5. Neutralisation of virus in vitro
To determine if the antibody induced by immunisation with to
RBD-Fc was neutralising for MERS-CoV in vitro, plaque assays were
performed. For this, two strains of MERS-CoV were used: London1-
2012 (GenBank accession number KC164505.2) [22] and Erasmus
Medical Center (EMC2012 Genbank accession number JX869059)
(21). The London1-2012 strain was obtained from the National Col-
lection of Pathogen Viruses, PHE Porton, Salisbury, UK and the
EMC2012 strain was kindly provided by the Erasmus University
Medical Center Rotterdam, the Netherlands. Both strains were pre-
pared in serum-free media (Gibco) at a multiplicity of infection
(MOI) of 0.01, equivalent to 103 plaque-forming units (pfu). The
murine antiserum for testing was prepared at a dilution range from
undiluted to 1:10 in PBS. Virus was incubated overnight (4 C) with
murine antiserum, negative control antibody (NIBSC, UK) or media,
prior to infection of a confluent monolayer of Vero E6 cells (ECACC,
Salisbury UK) with 200 ll of the mixture. The neutralising ability of
the murine antiserum was tested in duplicate or triplicate at each
dilution. After incubation (1 h, 37 C), an overlay comprising a 1:1
dilution of carboxymethyl cellulose with serum-free media wasadded to the cells and incubation continued for a further 4 days
(37 C) prior to fixing (7.4% formaldehyde) and staining (0.2% crys-
tal violet) with enumeration of the number of plaques per ml.
2.6. Murine infection with the MERS virus
Mice are not naturally susceptible to infection with MERS-CoV,
since they lack the human DPP4 receptor. To induce transient sus-
ceptibility in Balb/c mice, we used an Ad5 construct (Oxford Genet-
ics) to express the human DPP4 receptor (Ad5hDPP4), as
previously described (23). Mice were administered the Ad5hDPP4
construct (2.5  108 pfu in 50 ll) by the intra-nasal (i.n.) route
under light sedation with inhalational isofluorane and then moni-
tored by serial blood sampling for serum levels of hDPP4/CD26 by
ELISA (ThermoScientific). At peak levels of expression of hDPP4
(days 5–7), mice were lightly sedated as before and challenged
by the i.n. route with MERS-CoV (EMC2012 strain) at 104 pfu in
50 ll per mouse. Mice were weighed prior to challenge on each
subsequent day to monitor changes in body weight during
infection.
2.7. Neutralisation of virus in vivo by passive transfer of antibody
To test the in vivo neutralising capacity of murine antiserum
raised to the RBD-Fc construct, naïve mice (n = 10 per treatment
group) were passively immunised by the i.p. route at 24 h. prior
to i.n. challenge with the MERS Co-V (EMC2012 strain), as
described above. The murine antiserum, pooled from 4 mice who
had been primed with RBD-Fc PCMC and boosted orally (regimen
2, treatment group 2), was delivered at a dilution of 1:10 in PBS
and delivered in a total volume of 100 ll per mouse. A further
group of 10 mice received a purified polyclonal human IgG at a sin-
gle dose level (150 lg/mouse in 100 ll i.p.), which had been raised
to inactivated MERS-CoV. Control mice received a non-specific
human IgG at a single dose-level (200 lg/mouse in 100 ll, i.p.).
Both sets of human IgG (specific and non-specific) were raised in
a bovine transchromosomal model and purified prior to use. A fur-
ther group of 10 negative control mice were included, which
received PBS in place of either the Ad5DPP4 construct or the
MERS-CoV-specific antibody, and were also challenged i.n. with
MERS-CoV (EMC2012 strain) at 104 pfu/mouse. To determine the
protection afforded by the passive immunisation, pairs of mice
from each treatment group were culled on days 1–8 after challenge
and their lungs were removed and weighed and then rapidly fro-
zen (80 C) prior to the determination of viral load.
2.8. Determination of viral load in lungs
Pairs of lungs from each of 2 mice per treatment group were
individually thawed and homogenised in serum-free media
(2 ml). RNA was extracted from 140 ll of each homogenate using
the QiAamp Viral RNA kit (Qiagen), following the manufacturers’
instructions. Real-time PCR was conducted on duplicate 5 ll
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assay and reaction conditions [24]. As in Lu et al, we used the for-
ward primer GGGTGTACCTCTTAATGCCAATTC and reverse primer
TCTGTCCTGTCTCCGCCAAT with probe ACCCCTGCGCAAAATGCT
GGG. Each 25 ll reaction contained 6.25 ll TaqMan Fast Virus
1-Step mastermix (ThermoFisher Scientific); forward and reverse
primers (0.5 lM each), probe (0.1 lM), 5 ll RNA template and
10.25 ll water. A standard curve was constructed by spiking naïve
lung homogenate with MERS-CoV (EMC 2012) (final concentration
5  104 pfu/ml) and diluting in naïve lung homogenate to
0.5 pfu/ml. RNA was extracted from duplicate 140 ll aliquots of
each concentration and PCR conducted using the above method.
The amount of virus in tested samples was determined in duplicate
using the standard curve and reported as pfu/g lung tissue.
2.9. Statistical analysis
All data were analysed using Graph Pad Prism software v.6 and
expressed as mean ± s.e.m. Statistical comparisons were made
using one-way ANOVA or unpaired t-test.
3. Results
3.1. Expression and purification of RBD-Fc
The RBD-Fc protein was expressed in both adherent 293FT and
suspension human embryo kidney (HEK) cells, but with greater
expression in adherent cells (Fig. 1). Purification of protein from
adherent cells with Protein A was very effective, yielding protein
which was >99% pure, with molecular weight of approximately
100 kDa (Fig. 1A). The use of 1 M urea for elution was
optimum, as it was sufficient to solubilise the protein without
denaturing it, yielding RBD-Fc in optimum yield (0.2 mg/ml) andFig. 1. Expression and purification of RBD-Fc from suspension and adherent Human Emb
a 100 k Da protein by SDS-PAGE. Lanes 1 & 8: Load; Lanes 2 & 9: Flow through; Lanes 3–7
cells only: Lane 1: soluble protein; Lanes 3 & 4: protein precipitated on Protein A beadspredominantly in a dimeric form (Fig. 1B). This method of protein
purification was therefore selected for forward use.
3.2. Optimisation of RBD-Fc immunogenicity and assay of neutralising
activity
RBD-Fc, formulated for either sub-cutaneous (s.c.) or per oral
(p.o.) immunisation, was tested for immunogenicity and the for-
mulations optimised in an iterative approach. Initially, a s.c. dosing
regimen was used in which RBD-Fc was formulated in either alhy-
drogel or MF59 to deliver 2.5 lg of protein on each of three occa-
sions at 0, 10 and 31 days. Mice were monitored for 26 days after
the final boost and IgG titre determined (Fig. 2A). At day 70, the
total IgG titres achieved with RBD-Fc in alhydrogel or MF59 did
not differ significantly. To determine if the presentation of RBD-
Fc in either alhydrogel or MF59 influenced the ability to develop
virus-neutralising antibody, antisera were selected from 2 mice
in each immunisation group and tested in a plaque assay for neu-
tralisation of both the EMC2012 and London1-2012 strains of
MERS-CoV (Fig. 2B and C). All four sera gave some neutralisation
of viral activity, although at a 1:20 dilution, sera 136 and 169 were
most potent, against both viral strains. Sera 136 and 169 were
derived from the treatment group immunised with MF59-
adjuvanted RBD-Fc, whereas sera 132 and 150 were derived from
alhydrogel-adjuvanted RBD-Fc (Fig. 2A). Based on this pilot data,
we subsequently used MF59 as the conventional adjuvant for
RBD-Fc, to compare with some novel formulations.
3.3. Induction of systemic, mucosal and functional antibody to RBD-Fc
Having demonstrated to proof-of-principle that the RBD-Fc,
when delivered in MF59 can induce a high titre of antibody with
neutralising activity, we next investigated how to tailor anryo Kidney (HEK) cells. (A) Expression of RBD-Fc in suspension and adherent cells as
and 10–14: Eluates 1–5 (B) Coomassie-stained gel of protein purified from adherent
and eluted in 6 M urea and 1 M urea respectively.
Fig. 2. A. Development of RBD-specific murine IgG titres with time in response to RBD-Fc in MF59 or alhydrogel immunisation by the s.c. route on days 0, 10 and 31. The
coloured replicates indicate the serum samples from each group assayed (132-blue and 150-purple in the alhydrogel group) and 136-red and 169-green in the MF59 group)
and demonstrated to have neutralising activity in vitro for clinical strains of MERS-CoV. (B) shows the in vitro neutralisation of the London1-2012 strain by individual murine
antisera to RBD-Fc whilst (C) shows neutralisation of the EMC2012 strain.
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immunity, with the aim also of reducing to a 2-dose immunisation
regimen and increasing functional antibody. For this, we selected
novel formulations in which RBD-Fc protein was presented as
RBD-Fc-PCMC for s.c. priming and incorporated into mineral oil
(MO) for p.o. boosting. We compared the serum IgG response
achieved from this 2-dose dual route immunisation with thatFig. 3. (A) Serum IgG to RBD-Fc after dual- or single-route immunisation. Mice were imm
Fc in the oral formulation, or with RBD-Fc in MF59 s.c., each on day 21. The serum IgG r
booster doses. (B) shows the distribution of IgG1 or IgG2a isotypes induced by day 49 o
level, by unpaired t-test.induced to RBD-Fc delivered in MF59 in a 2-dose s.c. regimen
(Fig. 3). At 1 month after the booster dose, at day 49, there was
no significant difference in the serum IgG titres achieved, so that
the 2-dose dual-route immunisation with RBD-Fc-PCMC for s.c.
priming and incorporated in MO with excipients for p.o. boosting,
was just as immunogenic as the 2-dose s.c. immunisation with
RBD-Fc in MF59 (Fig. 3A). At day 49, the serum response tounised with RBD-Fc on PCMC or with RBD-Fc in MF59 s.c. and boosted p.o. with RBD-
esponse at days 14 and 35 of the schedule is shown in response to the priming and
f the immunisation schedule. Statistical significance was determined at the p < 0.05
R.R.C. New et al. / Vaccine 37 (2019) 4094–4102 4099RBD-Fc in the dual-route regimen was predominantly IgG1 biased,
whereas s.c. dosing with RBD-Fc in the presence of MF59 induced
both IgG1 and IgG2a (Fig. 3B).
Since dual route immunisation effectively induced serum IgG to
RBD-Fc, it was of interest to determine whether it could also effec-
tively induce mucosal immunity. In this study, the RBD-Fc-specific
IgA response was determined in serum and in faecal pellet extracts
from individual animals on day 49. In this case, the RBD-specific
IgA responses of mice immunised in the 2-dose dual route regimen
were compared with that of mice immunised by the oral route
twice, and with mice immunised by the s.c. route in MF59 twice,Fig. 4. Sub-cut priming with oral boosting is not inferior to oral priming and boosting in t
shows IgA titres frommice immunised with RBD-Fc on PCMC s.c. and boosted p.o. with th
Fc. Negative control mice were primed and boosted with RBD-Fc in MF59 s.c., or with e
p < 0.05 level, by unpaired t-test.
Table 2
Neutralisation of MERS-CoV in vitro.
In vitro neutralisation of MERS EMC2012 In vi
Pfu virus at dilutions of mouse serum Pfu v
Treatment Mouse ID 1:10 1:20 1:40 1:60 % neutralisation Trea
RBD-Fc PCMC
s.c/s.c.
1 0 0 0 0 100 RBD-
s.c/s2 0 0 0 0 100
3 0 0 0 0 100
4 0 0 0 0 100
5 0 0 0 0 100
RBD-Fc PCMC
s.c/oral
1 0 0 0 0 100 RBD
s.c/o2 0 0 4,6 4,8 100,100,85,85
3 0 0 1,1 0 100
4 0 1.0 2,1 0 100
5 0 0 0 0 100
RBD-Fc oral/oral 1 24,15 30,22 22,17 21,22 0 RBD-
2 19,12 11,21 26,16 17,32 0
3 16 5 21 n.d. 62
RBD-Fc/MF59 1 0 0 0 0 100 RBD-
2 0 0 0 0 100
Empty microcrystals 1 13,12 17,13 20,15 25,18 0 Emp
2 9,8 14,9 16,14 12,16 0
3 15,23 13,20 21,21 20,9 0
Virus only 1 23 26 33 22 0 Viru
2 28 32 42 29 0
3 28 31 22 29 0
4 31 19 24 28 0on exactly the same days (0,21) (Fig. 4). This comparison showed
that s.c. immunisation in MF59 did not induce serum IgA. However
s.c. priming with RBD-Fc-PCMC with p.o. boosting effectively
induced RBD-Fc-specific IgA and was not inferior to oral priming
and boosting in this effect in either serum (Fig. 4A) or faecal
extracts (Fig. 4B). However mice primed and boosted orally did
not develop RBD-specific systemic IgG (data not shown).
Additionally, day 49 sera from mice in all treatment groups
were tested for their ability to neutralise either strain of MERS-
CoV in vitro (Table 2). From this it can be seen that sera from 4
out of 5 mice in the dual route regimen were fully neutralisinghe induction of IgA, measured at day 49 in serum (A) and faecal extracts (B). The fig.
e oral formulation; or immunised and boosted p.o. with the oral formulation of RBD-
mpty PCMC s.c. plus oral vehicle p.o. Statistical significance was determined at the
tro neutralisation of MERS London 1–2012
irus at dilutions of mouse serum
tment Mouse ID 1:10 1:20 1:40 1:60 % neutralisation
FC PCMC
.c.
1 0 0 0 0 100
2 0 0 0 0 100
3 0 0 0 0 100
4 0 0 0 9,3 100
5 0 0 0 0 100
-FC PCMC
ral
1 0 0 0 0 100
2 0 7;6 6;5 25;26 100, 89,89,0
3 0 2;0 5;6 14;4 100, 97,91, 86
4 0 1;0 4;1 8;7 100,100,96, 88
5 0 1;0 2;2 6;2 100,100,97,91
FC oral/oral 1 25,
TNTC
44,
TNTC
TNTC TNTC 0
2 TNTC TNTC TNTC TNTC 0
3 18 28 TNTC N.D. 0
Fc/MF59 1 0 0 0 0 100
2 0 0 0 0 100
ty microcrystals 1 23;19 22;28 38;29 33;41 0
2 35;27 34;24 43;32 39;37 0
3 33;30 34;44 44;29 21;46 0
s only 1 61 60 65 45 0
2 58 46 52 52 0
3 70 56 56 71 0
4 47 52 44 55 0
4100 R.R.C. New et al. / Vaccine 37 (2019) 4094–4102in vitro for both strains (EMC2012 and London1-2012), when
tested at 1:60 dilution (Fig. 5A and B). In order to test whether
the in vitro neutralising activity translated into viral neutralisation
in vivo, sera from these 4 mice (highlighted in Table 2) were pooled
in equal aliquots at 1:10 dilution to enable a subsequent passive
transfer study.3.4. Use of Ad5hDPP4 to induce CD26 expression in naïve mice
In order to design the passive transfer study, it was necessary to
define the duration of expression of CD26 in murine lungs in vivo,
following induction with the Ad5hDPP4 construct. Mice dosed
with Ad5hDPP4 i.n. at T0 were culled in pairs and lung homoge-
nates prepared and assayed for CD26 expression. CD26 in lung tis-
sue was expressed in a time-dependent manner, with levels
peaking at day 3 and declining to day 17 (Fig. 6A), setting a suffi-
cient window to use the model for the determination of the protec-
tion against viral challenge afforded by the passive transfer of
MERS-specific antibody.Fig. 6. A. Expression of CD26 was induced in lung tissue by the administration of Ad5hD
pairs on the days shown and their lungs assayed for the expression of CD26. The plot sh
points were normalised for background values from control mice. 6B: Content of MERS-C
post-infection, (equivalent to day 4 after passive transfer with murine antisera to RBD-Fc
received either a MERS-CoV-specific human IgG (150 lg) or non-specific human IgG (200
4 murine donors and which was delivered at 1:10 dilution (100 ll/mouse i.p.). Negat
challenged with MERS-CoV EMC2012 i.n. at 104 pfu/mouse. Statistical significance was
Fig. 5. In vitro neutralisation of (A) MERS-CoV (London1-2012 strain) and (B) MERS-CoV (
route or single-route immunisation regimen.3.5. Neutralisation of virus in vivo by passive transfer of antibody
To determine the protection afforded by the passive transfer of
murine antiserum raised in the dual route immunisation regimen,
against infection, susceptibility to MERS-CoV was induced at T0
with i.n. administration of Ad5hDPP4 to groups of 10 mice. Passive
transfer by the i.p. route of the pooled serum sample derived from
the 4 mice highlighted in Table 2, which had previously been
shown to be neutralising in vitro (Table 2) was conducted 5 days
later and mice were challenged after a further 24 h with
MERS-CoV EMC2012. Additional groups of mice, which had been
transduced with Ad5hDPP4, were passively immunised with a
MERS-CoV specific human IgG and a non-specific human IgG. At
1–8 days after challenge, pairs of mice were culled for the determi-
nation of viral load in lungs, which was determined to peak at
3 days p.i. (data not shown). At 3 days p.i., the pooled murine anti-
serum significantly reduced viral titres in lungs, to the same extent
as the specific human IgG, and contrasting with the negative con-
trol human IgG, demonstrating significant in vivo neutralising
activity (Fig. 6B).PP4 (2.5  108 pfu) to mice by the i.n. route at T0. Subsequently, mice were culled in
ows the time-course of CD26 expression from 3 to 17 days post-induction. All data
oV (EMC2012 strain) in murine lungs (pfu/g tissue) determined by RT-PCR at day 3
which had previously been shown to neutralise the EMC2012 strain in vitro). Mice
lg) in 100 ll /mouse i.p.; or murine antisera to RBD-FC, which had been pooled from
ive control mice received PBS in place of Ad5hDPP4 or antiserum All mice were
determined at the p < 0.05 level by one way Anova and unpaired t-test.
EMC2012 strain) by individual murine antisera induced to RBD-Fc in either the dual-
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between treatment groups challenged with MERS-CoV, which
was attributed to the short time period of the study.4. Discussion
MERS is a serious endemic respiratory infectious disease for
which there is no licensed vaccine, although there are several vac-
cines in clinical trial currently including adenovirus-vectored
delivery of the Spike protein and sub-units [27], DNA vaccines
and nanoparticle-delivered sub-unit approaches [28]. We were
interested in determining the advantage of r a vaccine which could
induce mucosal as well as specific systemic immunity to the key
target, the RBD protein, in order to achieve optimum protective
efficacy. Vaccination to induce effective immunity at mucosal sur-
faces, should prime the immune system to respond rapidly to
invading pathogens such as MERS-CoV. Previous studies have used
adenovirus delivery of the MERS Spike protein with intra-muscular
(i.m.) or intra-gastric (i.g.) delivery to induce neutralising systemic
IgG, but not IgA; further, whilst i.m. delivery also induced specific
T-cell immunity, i.g. delivery did not [29]. Others have shown that
intra-nasal delivery of a live attenuated adenovirus-vectored sub-
unit vaccines does induce specific mucosal as well as systemic
immunity, although translation of this approach to the clinic may
raise safety issues [30]. Here, we have relied on novel formulations
of a sub-unit protein to enable dual route vaccination (parenteral
and oral) to induce mucosal as well as systemic immunity.
In this study, we have achieved the expression and purification
of a recombinant RBD-Fc protein in milligram quantities. We have
also demonstrated that when formulated as a sub-unit vaccine, the
construct induced murine antibody which effectively neutralised
two different clinical strains of MERS-CoV in vitro. Additionally,
we have shown that these murine antisera, when passively trans-
ferred into naïve mice transduced to express the hDPP4 /CD26
receptor, conferred protection against viral challenge in the recip-
ients, with significantly reduced viral loads in the lung tissue of the
recipient mice.
Whilst the use of conventional adjuvants such as MF59 or alhy-
drogel to formulate the RBD-Fc protein resulted in high titres of
specific IgG in serum, the MF59 formulation did not induce specific
IgA in serum. In order to promote both systemic and mucosal
immunity to RBD-Fc, we have formulated this protein for injected
priming and p.o. boosting, entailing the optimisation of the CaP
PCMC and of the reverse micelles in oil emulsion, respectively. This
has enabled the achievement of a vaccination regimen comprising
only two doses and rapidly inducing RBD-Fc-specific systemic and
mucosal immunity.
Whilst the PCMC formulation of RBD-Fc was as effective as RBD
in MF59 in inducing a primary IgG response, we have shown that
an oral formulation of RBD-Fc in mineral oil with selected
immunostimulants was as effective as MF59 when used as a boos-
ter immunisation. Additionally, we have shown that non-invasive
oral priming and boosting is as effective at inducing a specific
mucosal response, measured as specific IgA in serum and faeces,
as is injected priming with RBD-Fc in the PCMC formulation
together with oral boosting, leading to the exciting concept of a
potential orally-dosed sub-unit vaccine for MERS.
Whilst both alhydrogel and the combination of PCMC and oral
formulations are Th2-polarising, as evidenced by the predomi-
nantly IgG1 titres raised to RBD-Fc, the influence of MF59 on the
response to RBD-Fc was a mixed Th-2/Th1 effect, with a significant
induction of specific IgG1 and IgG2a. To counter a viral infection, it
would be expected that a Th1 response would be most appropriate.
However, the fact that neutralising antibody to RBD-Fc was raised
under either Th1 or Th2-polarising influences, suggests that eitherisotype can be protective and primes the immune system suffi-
ciently and would allow for cross-presentation to occur on subse-
quent exposure to the virus [31]. In this study, we have not
examined the induction of a cell-mediated memory response to
the RBD-Fc protein, although this will play a significant role in pro-
tection against the virus.
Currently, we are presenting the RBD protein in our formula-
tions with an Fc tag, derived from human IgG1 and useful in puri-
fying the protein. The Fc tag may contribute additional
adjuvantising activity by engaging antigen-presenting cells in the
vaccinee [32] and it may aid mucosal immunity since the Fc recep-
tor, an MHC1 transmembrane protein, is also expressed at mucosal
surfaces e.g. in the respiratory tract [33]. Vaccination of the zoono-
tic host, the dromedary camel, may also effectively curb outbreaks
of MERS in endemic regions and limit the risk of viral recombina-
tion [34] and significant progress with an orthopox-vectored vac-
cine for MERS has recently been reported [35]. The potential use
of a sub-unit vaccine for MERS in camel vaccination could be aided
by varying the sequence of the RBD protein [36] and substituting
the human Fc tag with an alternative tag recognised by the camel,
to design approaches tailored for animal vaccination, bearing in
mind that a single dose vaccine would be ideal in this context.
However, future work in our laboratory will also address the value
of retaining or removing the Fc tag from the RBD protein for clinical
or veterinary iterations of the vaccine.
In this study we have determined vaccine efficacy by demon-
strating in vitro and in vivo neutralising ability of murine antisera
raised in the dual route two-dose regimen against two virulent
clinical strains of MERS-CoV which have greater than 99% genome
sequence homologyy. In future work, it will be worthwhile to test
the efficacy of this approach against other clinical isolates of MERS-
CoV. This is the first report of a dual route dosing regimen applied
to a sub-unit vaccine for MERS-CoV. Future development of this
approach would require the direct testing of efficacy in the immu-
nised transduced mouse model. As well as giving a direct readout
of vaccine efficacy, this will enable the identification of the
immune correlates of protection, ready for transitioning this candi-
date vaccine into more extensive pre-clinical testing and clinical
development.
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